Siemens Healthineers has cut the red ribbon on a new €10m ($11.85m) centre of excellence focused on immunoassay instrument R&D in Swords, Ireland.
The centre, situated in a facility nearby Siemens existing operations in the region, will primarily focus on the further development of Siemens Healthineers’ Atellica advanced immunoassay and chemistry analysers.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Siemens Healthineers’ Atellica systems are designed to process bodily fluids such as blood and plasma in laboratory settings for disease diagnosis across areas including cardiac, oncology, and renal function. According to the company, Atellica has an installed base of over 2,000 systems across the US.
The centre’s opening reflects the culmination of an investment plan Siemens Healthineers initiated in 2023 with support from the Irish Government’s promotional arm, the Industrial Development Agency (IDA) Ireland. Further investment is planned in the future.
According to IDA Ireland CEO Michael Lohan, the facility’s opening reinforces Ireland’s position as a “global hub for innovation” in diagnostics and life sciences.
Patrick Grimes, global head of hardware engineering R&D for Siemens Healthineers Diagnostics, commented: “For nearly 60 years, this site has delivered world-class diagnostic instruments to hospitals and laboratories globally.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Now, by aligning research and development with production under one roof, we are accelerating the pace of discovery and delivery.”
IDA has also awarded Siemens Healthineers with a training and development grant of an undisclosed sum that is intended to support a ‘multi-million euro’ upskilling programme over the next three to five years.
This initiative will advance workforce capabilities for the medtech company across areas including advanced engineering, operations and leadership, with the overall aim to ensure that employees are equipped to “drive innovation and build sustainable careers” in the medtech and life sciences sector.
IDA’s grant resonates with advisement from Irish Medtech, which highlighted that access to a skilled workforce were among growing concerns for participants in the sector in a report published in March 2025.
In the trade body’s report, 63% of respondents cited attracting and retaining a quality workforce as a major challenge.
To alleviate this and associated concerns, such as labour costs and housing for employees, Irish Medtech director Eoghan Ó Faoláin called on the Irish government to focus on four key pillars to ensure sustained growth and development. These included supporting apprenticeship programmes to “promote lifelong learning” and advance gender leadership in the medtech sector.
The future of Siemens Healthineers
In November 2025, Siemens announced plans to exit the healthcare space and ‘deconsolidate’ its remaining stake in Siemens Healthineers by transferring 30% of shares to Siemens shareholders.
The German technology conglomerate stated that its 67% share stake in the Healthineers business would be handed over via a direct spin-off as a ‘preferable option’.
Siemens claimed it had taken the decision following a ‘thorough assessment’ and strategic review into how both companies could best realise their full potential, accelerate their respective transformations, and successfully tap into new areas of growth. Siemens has pledged to provide an update on the transaction in Q2 2026.
According to a report by Reuters, following the announcement, Siemens Healthineers CEO Bernd Montag said that the company was mulling an exit from its diagnostics division over the medium term, although no talks with interested parties have materialised as yet.
In November 2025, Siemens Healthineers announced EBIT of ‘just under’ €3.9bn ($4.62bn) in its fiscal year 2025 (FY25), with revenue growth for FY26 anticipated to fall between 5% and 6%.
